A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 May 2017
At a glance
- Drugs LMP1-LMP2-specific T lymphocyte therapy (Primary) ; Rituximab (Primary)
- Indications Lymphoproliferative disorders
- Focus Therapeutic Use
- 22 May 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 08 Mar 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2021.